Abstract: Background: Gestational diabetes mellitus (GDM) poses significant risks during pregnancy for both mother and fetus. Adherence to oral antidiabetic medications, like glibenclamide (GB), can be challenging, necessitating novel drug delivery methods. Nanostructured lipid carriers (NLC) offer a promising approach by efficiently permeating the skin due to their small size and lipid-based composition.
Objective: This study aimed to develop and evaluate transdermal patches loaded with glibenclamide NLCs to treat GDM.
Methods: Glibenclamide NLCs were prepared using hot homogenization with ultrasonication and melt dispersion method. A central composite design was utilized to optimize the formulations. Transdermal patches containing optimized NLCs were developed using HPMC K 100 and Eudragit L polymers. The patches were evaluated for various parameters, and their pharmacokinetic and pharmacodynamic studies were carried out to assess their safety and efficacy.
Results: Optimized NLCs efficiently permeated rat skin. Cell viability studies indicated the nontoxicity of the formulations. NLC-loaded transdermal patches (F2 and F7) showed drug release of 1098 μg/cm
2 and 1001.83 μg/cm
2 in 24 h, with a 2.5-fold higher flux and permeation coefficient than the GB patch. Pharmacokinetic analysis revealed Tmax of 8 and 10 h and C
max of 7127 ng/ml and 7960 ng/ml for F2 and F7, respectively, ensuring sustained drug action. AUC0-α was 625681 ng/ml·h and 363625 ng/ml·h for F2 and F7, respectively, indicating improved bioavailability.
Conclusion: Transdermal patches incorporating NLCs hold promise for enhancing glibenclamide's therapeutic efficacy in GDM treatment. Improved skin permeation, sustained drug release, and enhanced bioavailability make NLC-based transdermal patches a potential alternative with better patient compliance.
(Copyright© Bentham Science Publishers; For any queries, please email at
[email protected].)
Hollander M.H; Paarlberg K.M; Huisjes A.J.M; Gestational diabetes: A review of the current literature and guidelines. Obstet Gynecol Surv 2007,62(2),125-136. (PMID: 10.1097/01.ogx.0000253303.92229.5917229329)
Serlin D.C; Lash R.W; Diagnosis and management of gestational diabetes mellitus. Am Fam Physician 2009,80(1),57-62. (PMID: 19621846)
Crowther C.A; Hiller J.E; Moss J.R; McPhee A.J; Jeffries W.S; Robinson J.S; Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005,352(24),2477-2486. (PMID: 10.1056/NEJMoa04297315951574)
Behzadifar S; Barras A; Plaisance V; Pawlowski V; Szunerits S; Abderrahmani A; Boukherroub R; Polymer-based nanostructures for pancreatic beta-cell imaging and non-invasive treatment of diabetes. Pharmaceutics 2023,15(4),1215. (PMID: 10.3390/pharmaceutics1504121537111699)
Kalra S; Gupta Y; Kalra B; Singla R; Use of oral anti-diabetic agents in pregnancy: A pragmatic approach. N Am J Med Sci 2015,7(1),6-12. (PMID: 10.4103/1947-2714.15008125709972)
Ali H.S.M; Hanafy A.F; Glibenclamide nanocrystals in a biodegradable chitosan patch for transdermal delivery: Engineering, formulation, and evaluation. J Pharm Sci 2017,106(1),402-410. (PMID: 10.1016/j.xphs.2016.10.01027866687)
Ramadon D; McCrudden M.T.C; Courtenay A.J; Enhancement strategies for transdermal drug delivery systems: Current trends and applications. Drug Deliv Transl Res 2021,1-34. (PMID: 33474709)
Sezer A.D; Application of Nanotechnology in Drug Delivery 2014. (PMID: 10.5772/57028)
Ghate V.M; Lewis S.A; Prabhu P; Dubey A; Patel N; Nanostructured lipid carriers for the topical delivery of tretinoin. Eur J Pharm Biopharm 2016,108,253-261. (PMID: 10.1016/j.ejpb.2016.07.02627519827)
Iqbal B; Ali J; Baboota S; Silymarin loaded nanostructured lipid carrier: From design and dermatokinetic study to mechanistic analysis of epidermal drug deposition enhancement. J Mol Liq 2018,255,513-529. (PMID: 10.1016/j.molliq.2018.01.141)
Maroju R.K; Barash S; Brisbane C.E; Evaluation of a biologic formulation using customized design of experiment and novel multidimensional robustness diagrams. J Pharm Sci 2018,107(3),797-806.
Gupta S; Kesarla R; Chotai N; Misra A; Omri A; Systematic approach for the formulation and optimization of solid lipid nanoparticles of efavirenz by high pressure homogenization using design of experiments for brain targeting and enhanced bioavailability. BioMed Res Int 2017,2017,1-18. (PMID: 10.1155/2017/598401428243600)
Uprit S; Kumar Sahu R; Roy A; Pare A; Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm J 2013,21(4),379-385. (PMID: 10.1016/j.jsps.2012.11.00524227958)
Poonia N; Kaur Narang J; Lather V; Beg S; Sharma T; Singh B; Pandita D; Resveratrol loaded functionalized nanostructured lipid carriers for breast cancer targeting: Systematic development, characterization and pharmacokinetic evaluation. Colloids Surf B Biointerfaces 2019,181,756-766. (PMID: 10.1016/j.colsurfb.2019.06.00431234063)
Pastor M; Basas J; Vairo C; Gainza G; Moreno-Sastre M; Gomis X; Fleischer A; Palomino E; Bachiller D; Gutiérrez F.B; Aguirre J.J; Esquisabel A; Igartua M; Gainza E; Hernandez R.M; Gavaldà J; Pedraz J.L; Safety and effectiveness of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against P. aeruginosa: In vitro and in vivo studies following pulmonary and intramuscular administration. Nanomedicine (Lond) 2019,18,101-111. (PMID: 10.1016/j.nano.2019.02.01430849549)
Aliasgharlou L; Ghanbarzadeh S; Azimi H; Zarrintan M.H; Hamishehkar H; Nanostructured lipid carrier for topical application of N-acetyl glucosamine. Adv Pharm Bull 2016,6(4),581-587. (PMID: 10.15171/apb.2016.07228101465)
Marrese M; Guarino V; Ambrosio L; Atomic force microscopy: A powerful tool to address scaffold design in tissue engineering. J Funct Biomater 2017,8(1),7. (PMID: 10.3390/jfb801000728208801)
Kang Q; Liu J; Liu X.Y; Mo N.L; Wang Y.J; Zhao Y; Liu X; Wu Q; Application of quality by design approach to formulate and optimize tripterine loaded in nanostructured lipid carriers for transdermal delivery. J Drug Deliv Sci Technol 2019,52,1032-1041. (PMID: 10.1016/j.jddst.2019.06.006)
Luruli N; Pijpers T; Brüll R; Grumel V; Pasch H; Mathot V; Fractionation of ethylene/1‐pentene copolymers using a combination of SEC‐FTIR and SEC‐HPer DSC. J Polym Sci, B, Polym Phys 2007,45(21),2956-2965. (PMID: 10.1002/polb.21127)
Injem V.K; Sudheer P; Ashwini M; Formulation and evaluation of topical solid lipid nanoparticulate system of clobetasole propionate. Der Pharma Chem 2017,9(22),29-37.
Bhaskar K; Krishna Mohan C; Lingam M; Prabhakar Reddy V; Venkateswarlu V; Madhusudan Rao Y; Development of nitrendipine controlled release formulations based on SLN and NLC for topical delivery: In vitro and ex vivo characterization. Drug Dev Ind Pharm 2008,34(7),719-725. (PMID: 10.1080/0363904070184248518612912)
Shakeel F; Baboota S; Ahuja A; Ali J; Shafiq S; Skin permeation mechanism and bioavailability enhancement of celecoxib 2011,107-120.
Singh Hallan S; Sguizzato M; Pavoni G; Baldisserotto A; Drechsler M; Mariani P; Esposito E; Cortesi R; Ellagic acid containing nanostructured lipid carriers for topical application: A preliminary study. Molecules 2020,25(6),1449. (PMID: 10.3390/molecules2506144932210106)
Vijayan V; Jayachandran E; Anburaj J; Rao D.S; Kumar K.J; Transdermal delivery of repaglinide from solid lipid nanoparticles in diabetic rats: In vitro and in vivo Studies. J Pharm Sci Res 2011,3(3),1077.
Nayak B; Pattanayak D; Ellaiah P; Das S; Formulation design preparation and in vitro characterization of nebivolol transdermal patches. Asian J Pharm 2011,5(3),175-182. (PMID: 10.4103/0973-8398.91994)
Trivedi D; Goyal A; Formulation and evaluation of transdermal patches containing dexketoprofen trometamol. Int J Pharm Chem Anal 2020,7(2),87-97. (PMID: 10.18231/j.ijpca.2020.014)
Seyed Yagoubi A; Shahidi F; Mohebbi M; Varidi M; Golmohammadzadeh S; Preparation, characterization and evaluation of physicochemical properties of phycocyanin-loaded solid lipid nanoparticles and nanostructured lipid carriers. J Food Meas Charact 2018,12(1),378-385. (PMID: 10.1007/s11694-017-9650-y)
Bhowmick M; Evaluation and characterization of transdermal therapeutic systems: An exhaustive pictorial and figurative review. J Drug Deliv Ther 2016,4(6),8-22.
Banerjee S; Chattopadhyay P; Ghosh A; Pathak M.P; Singh S; Veer V; Acute dermal irritation, sensitization, and acute toxicity studies of a transdermal patch for prophylaxis against (+/-) anatoxin-a poisoning. Int J Toxicol 2013,32(4),308-313. (PMID: 10.1177/109158181348999623696561)
Mandava K; Cherukuri S; Batchu U.R; Cherukuri V; Ganapuram K; Formulation and evaluation of transdermal drug delivery of topiramate. Int J Pharm Investig 2017,7(1),10-17. (PMID: 10.4103/jphi.JPHI_35_1628405574)
Nair A; Jacob S; A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 2016,7(2),27-31. (PMID: 10.4103/0976-0105.17770327057123)
Li Y; Wei Y; Zhang F; Wang D; Wu X; Changes in the pharmacokinetics of glibenclamide in rats with streptozotocin-induced diabetes mellitus. Acta Pharm Sin B 2012,2(2),198-204. (PMID: 10.1016/j.apsb.2012.01.005)
Tipre D.N; Vavia P.R; Formulation optimization and stability study of transdermal therapeutic system of nicorandil. Pharm Dev Technol 2002,7(3),325-332. (PMID: 10.1081/PDT-12000572912229264)
Processing Request
No Comments.